Fennec Pharmaceuticals Reveals Pricing for Common Shares Offering
Public Offering Announcement: Fennec Pharmaceuticals has priced an underwritten public offering of 4,666,667 common shares at $7.50 per share, with expected gross proceeds of approximately $35 million, closing on November 17, 2025.
Use of Proceeds: The company plans to use the net proceeds to repurchase certain debts and for general corporate purposes.
Product Focus: Fennec is dedicated to combating ototoxicity in cancer patients through its FDA-approved product, PEDMARK®, which is now available in multiple regions including the U.K. and Germany.
Forward-Looking Statements: The company has issued forward-looking statements regarding the offering and acknowledges various risks that could impact its business and product development.
Trade with 70% Backtested Accuracy
Analyst Views on FENC
About FENC
About the author
B. Riley Begins Coverage of Fennec Pharmaceuticals Inc. with a Buy Rating and $16 Price Target
Company Overview: Fennec Pharmaceuticals has initiated coverage with a buy rating from B. Riley.
Target Price: The target price set for Fennec Pharmaceuticals is $16.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the outstanding shares.
- Market Strategy: This sale indicates a strategic adjustment in Southpoint's investment portfolio, as it still controls 2.7 million shares, but the reduced stake may reflect a cautious outlook on market conditions.
- Compliance Disclosure: The press release serves to comply with securities regulations, ensuring transparency and maintaining market trust, highlighting Southpoint's commitment to regulatory adherence.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions or other means, indicating flexibility in its investment strategy.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the total outstanding shares.
- Market Strategy: The shares sold represent about 2.93% of Fennec's total outstanding shares, indicating Southpoint's flexible investment strategy in response to changing market conditions, which could impact Fennec's stock performance.
- Ownership Adjustment: Following this transaction, Southpoint retains control over 2.7 million shares of Fennec, reflecting ongoing interest in the company, although the reduction may suggest a response to short-term market volatility.
- Future Outlook: Southpoint indicated that it may further adjust its ownership of Fennec based on market and other conditions, demonstrating its proactive and flexible approach to investment management.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposal: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its stake to approximately 8%, indicating a potential shift in its investment strategy regarding the company.
- Market Impact: This transaction decreases Southpoint's control to 2.7 million shares, representing about 8% of the outstanding shares, reflecting its strategy to adjust its portfolio in response to changing market conditions for optimized returns.
- Investment Purpose: The share disposal was executed for investment purposes, suggesting Southpoint's intent to seek higher returns while maintaining flexibility to respond to market dynamics.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions, private agreements, or other means, demonstrating its adaptability and strategic flexibility in a dynamic market environment.
Fennec Pharmaceuticals Initiates Study of PEDMARK® to Reduce Ototoxicity in Adult Testicular Cancer Patients
- Study Initiation: Fennec Pharmaceuticals announced an investigator-sponsored study by City of Hope to evaluate PEDMARK® for preventing ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors, reflecting growing clinical interest in addressing chemotherapy-induced hearing loss.
- Clinical Need: Research indicates that 60-90% of patients treated with cisplatin may experience hearing loss, and the application of PEDMARK® could significantly enhance the quality of life for these patients, addressing an increasing clinical demand.
- Market Potential: Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by cisplatin, and the FDA approval of PEDMARK® opens new market opportunities for its use in adult patients, which is expected to drive future commercial growth for the company.
- Strategic Collaborations: Fennec is collaborating with multiple research institutions to advance studies on PEDMARK® in metastatic diseases, aiming to expand its clinical evidence base and enhance its competitive position in the market.
Pedmark Shows Promising Results in Japan Study — Reduced Hearing Loss with Equivalent Cancer-Fighting Efficacy
Study Results: Fennec Pharmaceuticals announced positive topline results from the Phase 2/3 STS-J01 trial of Pedmark, showing reduced rates of cisplatin-induced ototoxicity in pediatric patients, with only 24% and 16% experiencing hearing loss compared to higher rates in previous trials.
Safety and Efficacy: The study confirmed that Pedmark does not interfere with the antitumor activity of cisplatin, maintaining a high tumor response rate of approximately 95%, and was well-tolerated with no adverse events attributed to the drug.
Future Plans: Fennec intends to pursue regulatory registration for Pedmark in Japan and explore potential partnerships or licensing opportunities, with full study results to be presented in a scientific forum and submitted for publication.
Market Reaction: Following the announcement, Fennec Pharmaceuticals' stock experienced a slight decline of 0.78%, trading at $7.85.
B. Riley Begins Coverage of Fennec Pharmaceuticals Inc. with a Buy Rating and $16 Price Target
Company Overview: Fennec Pharmaceuticals has initiated coverage with a buy rating from B. Riley.
Target Price: The target price set for Fennec Pharmaceuticals is $16.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the outstanding shares.
- Market Strategy: This sale indicates a strategic adjustment in Southpoint's investment portfolio, as it still controls 2.7 million shares, but the reduced stake may reflect a cautious outlook on market conditions.
- Compliance Disclosure: The press release serves to comply with securities regulations, ensuring transparency and maintaining market trust, highlighting Southpoint's commitment to regulatory adherence.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions or other means, indicating flexibility in its investment strategy.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the total outstanding shares.
- Market Strategy: The shares sold represent about 2.93% of Fennec's total outstanding shares, indicating Southpoint's flexible investment strategy in response to changing market conditions, which could impact Fennec's stock performance.
- Ownership Adjustment: Following this transaction, Southpoint retains control over 2.7 million shares of Fennec, reflecting ongoing interest in the company, although the reduction may suggest a response to short-term market volatility.
- Future Outlook: Southpoint indicated that it may further adjust its ownership of Fennec based on market and other conditions, demonstrating its proactive and flexible approach to investment management.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposal: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its stake to approximately 8%, indicating a potential shift in its investment strategy regarding the company.
- Market Impact: This transaction decreases Southpoint's control to 2.7 million shares, representing about 8% of the outstanding shares, reflecting its strategy to adjust its portfolio in response to changing market conditions for optimized returns.
- Investment Purpose: The share disposal was executed for investment purposes, suggesting Southpoint's intent to seek higher returns while maintaining flexibility to respond to market dynamics.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions, private agreements, or other means, demonstrating its adaptability and strategic flexibility in a dynamic market environment.
Fennec Pharmaceuticals Initiates Study of PEDMARK® to Reduce Ototoxicity in Adult Testicular Cancer Patients
- Study Initiation: Fennec Pharmaceuticals announced an investigator-sponsored study by City of Hope to evaluate PEDMARK® for preventing ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors, reflecting growing clinical interest in addressing chemotherapy-induced hearing loss.
- Clinical Need: Research indicates that 60-90% of patients treated with cisplatin may experience hearing loss, and the application of PEDMARK® could significantly enhance the quality of life for these patients, addressing an increasing clinical demand.
- Market Potential: Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by cisplatin, and the FDA approval of PEDMARK® opens new market opportunities for its use in adult patients, which is expected to drive future commercial growth for the company.
- Strategic Collaborations: Fennec is collaborating with multiple research institutions to advance studies on PEDMARK® in metastatic diseases, aiming to expand its clinical evidence base and enhance its competitive position in the market.
Pedmark Shows Promising Results in Japan Study — Reduced Hearing Loss with Equivalent Cancer-Fighting Efficacy
Study Results: Fennec Pharmaceuticals announced positive topline results from the Phase 2/3 STS-J01 trial of Pedmark, showing reduced rates of cisplatin-induced ototoxicity in pediatric patients, with only 24% and 16% experiencing hearing loss compared to higher rates in previous trials.
Safety and Efficacy: The study confirmed that Pedmark does not interfere with the antitumor activity of cisplatin, maintaining a high tumor response rate of approximately 95%, and was well-tolerated with no adverse events attributed to the drug.
Future Plans: Fennec intends to pursue regulatory registration for Pedmark in Japan and explore potential partnerships or licensing opportunities, with full study results to be presented in a scientific forum and submitted for publication.
Market Reaction: Following the announcement, Fennec Pharmaceuticals' stock experienced a slight decline of 0.78%, trading at $7.85.
